Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Главный автор: | Leng, H |
---|---|
Другие авторы: | Simon, K |
Формат: | Диссертация |
Язык: | English |
Опубликовано: |
2019
|
Предметы: |
Схожие документы
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
по: Mabilleau, G, и др.
Опубликовано: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
по: Adamopoulos, I, и др.
Опубликовано: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
по: Mabilleau, G, и др.
Опубликовано: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
по: Magetsari, Rahadyan, и др.
Опубликовано: (2022) -
Maintenance therapy in multiple myeloma
по: Jean-Luc Harousseau
Опубликовано: (2009-08-01)